Patient Guide: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 17 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06388200
Status: 🟢 Enrolling Now
Condition: Retinitis Pigmentosa
Phase: PHASE3

Where You Can Participate

This study is available at 17 locations across the country.

Top locations include:
  • • Phoenix, Arizona
  • • La Jolla, California
  • • Los Angeles, California
  • • And 14 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa - Join Clinical Trial NCTNCT06388200

How to Join This Clinical Trial - NCTNCT06388200

Learn how to participate in this PHASE3 trial studying an investigational therapy for Retinitis Pigmentosa. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Retinitis Pigmentosa. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Retinitis Pigmentosa
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06388200 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 17 locations. Find a study site near you:

Clinical Research Site

Phoenix, Arizona 85020 - United States

Status: RECRUITING

Clinical Research Site

La Jolla, California 92093 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90033 - United States

Status: RECRUITING

Clinical Research Site

Deerfield Beach, Florida 33064 - United States

Status: RECRUITING

Clinical Research Site

Miami, Florida 33136 - United States

Status: RECRUITING

Clinical Research Site

Erie, Pennsylvania 16507 - United States

Status: RECRUITING

Clinical Research Site

Nashville, Tennessee 37232 - United States

Status: RECRUITING

Clinical Research Site

Bellaire, Texas 77401 - United States

Status: RECRUITING

Clinical Research Site

Dallas, Texas 75231 - United States

Status: RECRUITING

Clinical Research Site

Houston, Texas 77030 - United States

Status: NOT_YET_RECRUITING

And 7 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Retinitis Pigmentosa:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships